Status:
COMPLETED
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Migraine
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to naratriptan hydrochloride or any comparable or similar product.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01161667
Start Date
September 1 2007
End Date
September 1 2007
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charles River Northwest Kinetics
Tacoma, Washington, United States, 98418